Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°£³»¼±¾ÏÁ¾ °¨º°À» À§ÇÑ Á¾¾çÇ¥Áö´Ü¹éÀÇ ¹ßÇö ¾ç»ó Expression Patterns of Tumor Related Proteins for Differential Diagnoses of Intrahepatic Adenocarcinomas

´ëÇѺ´¸®ÇÐȸÁö 2005³â 39±Ç 4È£ p.229 ~ 235
À±±æ¼÷, ¹èÇÑÀÍ, ±èż÷, ±è¹Ì¼º, ÀÌ¿µÈ­, ¾öÁöÇö, ±è¼±ÁÖ, ¼­Àμö,
¼Ò¼Ó »ó¼¼Á¤º¸
À±±æ¼÷ ( Yun Kil-Suk ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

¹èÇÑÀÍ ( Bae Han-Ik ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±èż÷ ( Kim Tae-Sook ) 
ÀÎÇÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±è¹Ì¼º ( Kim Mi-Sung ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
ÀÌ¿µÈ­ ( Lee Young-Hwa ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¾öÁöÇö ( Uhm Ji-Hyun ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±è¼±ÁÖ ( Kim Sun-Joo ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¼­Àμö ( Suh In-Su ) 
°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Background: Differential diagnoses of intrahepatic adenocarcinomas (IHAC) play an important role in the detecting primary sites and the determining type of treatment and overall prognosis of the patient. However, histopathologic findings alone have limitations of differential diagnoses of IHAC.

Methods: To clarify which tumor related proteins (TRP) are useful for differential diagnoses of IHAC, TRP expression were investigated immunohistochemically, using MUC5AC, MUC2, mAb 91.9H, MUC1, and pS2, and by high iron diamine (HID) staining in 61 clinically confirmed IHACs.

Results: MUC5AC (9/18, p<0.05) and MUC1 (17/18, p>0.05) displayed the most frequent expression in cholangiocarcinomas, and MUC2 (11/18, p<0.05), mAb 91.9H (16/18, p<0.05), and HID (16/18, p<0.05) in colorectal adenocarcinomas. pS2 (3/11, p>0.05) was expressed more often in pancreatic adenocarcinomas than other IHAC, while MUC2 and 91.9H were not expressed at all in pancreatic adenocarcinomas. The positivity of several TRP did not correlate with tumor differentiation.

Conclusions: MUC5AC, MUC2, mAb 91.9H, and HID may be useful in differentiating cholangiocarcinomas from colorectal adenocarcinomas.

Å°¿öµå

Cholangiocarcinoma;Metastatic adenocarcinoma;MUC5AC;MUC2 MUC1;mAb91.9H;pS2;HID

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS